Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Rifabutin
100%
HIV-related
100%
Twice Daily
100%
Mycobacterium Tuberculosis (M. tb)
100%
Rifamycin Resistance
100%
Treatment Failure
80%
Clinical Relapse
60%
CD4 Lymphocyte Count
60%
Antiretroviral Therapy
40%
Positive Treatment
40%
95% Confidence Interval
40%
Ethambutol
20%
Rifampin
20%
High Risk
20%
Tuberculosis Treatment
20%
Adverse Events
20%
Thrice Weekly
20%
Advanced HIV Disease
20%
Pyrazinamide
20%
Direct Supervision
20%
Tuberculosis Control Programme
20%
Baseline CD4
20%
During Treatment
20%
Well Tolerated
20%
Low CD4
20%
CD4 Cell Count
20%
Nursing and Health Professions
Human Immunodeficiency Virus
100%
Rifamycin
100%
Tuberculosis
100%
Rifabutin
100%
CD4 Lymphocyte Count
80%
Treatment Failure
80%
Confidence Interval
40%
Isoniazid
40%
Antiretroviral Therapy
40%
Ethambutol
20%
Tuberculosis Control
20%
Adverse Event
20%
Rifampicin
20%
Diseases
20%
Pyrazinamide
20%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Rifamycin
100%
Rifabutin
100%
Tuberculosis
100%
Lymphocyte
60%
Isoniazid
40%
Antiretroviral Therapy
40%
Ethambutol
20%
Cell Count
20%
Tuberculosis Treatment
20%
Prospective Study
20%
Rifampicin
20%
Pyrazinamide
20%
Diseases
20%
Adverse Event
20%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Rifamycin
100%
Tuberculosis
100%
Rifabutin
83%
Isoniazid
33%
Ethambutol
16%
Adverse Event
16%
Prospective Study
16%
Rifampicin
16%
Pyrazinamide
16%
Diseases
16%
Immunology and Microbiology
Human Immunodeficiency Virus
100%
CD4 Lymphocyte Count
100%
Rifamycin
100%
CD4
25%